Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the U.S.
Abingworth, the international investment group dedicated to life sciences, today announced that it has seeded GammaDelta Therapeutics Ltd, a new immunotherapy company. GammaDelta Therapeutics also received support from three organisations, Cancer Research Technology (CRT), King’s College London and the Francis Crick Institute. The company is being incubated at Abingworth’s London
“I am very pleased that Reinhard has accepted the role of CFO of the Group, and I am also proud to welcome Magnus Lundbäck back to Getinge. Both have comprehensive experience of the Group and in-depth expertise
in their respective fields,” Joacim Lindoff, Acting President and CEO of Getinge.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals Inc. announced today that it has completed a $5
million Series A financing to support its upcoming Phase II trial in
patients with Amyotrophic Lateral Sclerosis (ALS). Morningside Venture
led the financing and was joined by the ALS Investment Fund and former
Genzyme CEO Henri Termeer, as well as new